Dapagliflozin, Liraglutide, and Their Combination Attenuate Diabetes Mellitus-Associated Hepato-Renal Injury—Insight into Oxidative Injury/Inflammation/Apoptosis Modulation

In this study, we aim to explore the beneficial therapeutic impacts of dapagliflozin (Dapa), a highly potent, reversible, and selective sodium–glucose cotransporter-2 inhibitor, and liraglutide (Lira), a glucagon-like peptide-1 (GLP-1) receptor agonist, as hypoglycaemic agents for the management of...

Descripción completa

Detalles Bibliográficos
Autores principales: El-Sherbiny, Mohamed, El-Shafey, Mohamed, Said, Eman, Shaker, Gehan Ahmed, El-Dosoky, Mohamed, Ebrahim, Hasnaa Ali, Abed, Sally Yussef, Ibraheem, Khalid M., Mohsen Faheem, Ahmed, AlMutawa, Muntazar, Alatawi, Bayader, Elsherbiny, Nehal M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9144980/
https://www.ncbi.nlm.nih.gov/pubmed/35629430
http://dx.doi.org/10.3390/life12050764

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9144980/
https://www.ncbi.nlm.nih.gov/pubmed/35629430
http://dx.doi.org/10.3390/life12050764

Ejemplares similares